TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sébastien Viel(Université Claude Bernard Lyon 1), Thierry Walzer(Université Claude Bernard Lyon 1), Emily Charrier(Lyon 1 Université), Christophe Caux(Université Claude Bernard Lyon 1), Julien C. Marie(Université Claude Bernard Lyon 1), Jessica Rabilloud(Lyon 1 Université), Amélien Sanlaville(Centre National de la Recherche Scientifique), David K. Finlay(Trinity College), Antoine Marçais(Université Claude Bernard Lyon 1), Morgan Grau(Lyon 1 Université), Mark J. Smyth(Peter MacCallum Cancer Centre), Liam Town(QIMR Berghofer Medical Research Institute), Jacqueline Marvel(Lyon 1 Université), Sophie Degouve(Université Claude Bernard Lyon 1), Laurent Bartholin(Université Claude Bernard Lyon 1), Nicholas D. Huntington(The University of Melbourne), Fernando Guimarães(The University of Queensland), Sophia Djebali(Lyon 1 Université), Jacques Bienvenu(Lyon 1 Université), Róisín M. Loftus(Trinity College Dublin)
Cited by 647
Related Papers
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
|Proceedings of the National Academy of Sciences|2008|843
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
|Autoimmunity Reviews|2020|693
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639